Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Mural Oncology PLC MURA

Healthcare Biotechnology
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat... see more

Recent & Breaking News (NDAQ:MURA)

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 4, 2025

Mural Oncology Announces Plans to Explore Strategic Alternatives

GlobeNewswire April 15, 2025

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

GlobeNewswire March 25, 2025

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

GlobeNewswire March 11, 2025

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 18, 2025

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

GlobeNewswire January 9, 2025

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2024

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

GlobeNewswire November 20, 2024

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

GlobeNewswire November 13, 2024

Mural Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 11, 2024

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 7, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2024

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 7, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2024

Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

GlobeNewswire September 26, 2024

Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

GlobeNewswire September 23, 2024

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

GlobeNewswire September 10, 2024

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 4, 2024

Mural Oncology to Present at Two Upcoming Investor Conferences

GlobeNewswire August 27, 2024

Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress

GlobeNewswire August 13, 2024

Podcasts